Company profile: BigHat Biosciences
1.1 - Company Overview
Company description
- Provider of AI-guided antibody design and protein therapeutics via the Milliner platform integrating high-speed synthetic biology wet lab with machine learning to accelerate discovery and engineering; Reccy cloud-native LIMS/OS for instrument/robot control, scheduling, data management, and ML training; develops antibodies for oncology, inflammatory diseases, and immunology; partners with biopharma/biotech.
Products and services
- Antibody Therapeutics: Develops therapeutic antibodies for oncology, inflammatory diseases, and immunology, focusing on next-generation formats like camelid and human VHHs, scFvs, multispecifics, and conjugates
- Milliner™ Platform: Engineers an AI-guided, full-stack antibody discovery and engineering platform integrating synthetic biology-based high-speed wet lab with machine learning technologies to create better antibodies faster
- Reccy™: A custom-built, cloud-native LIMS and operating system overseeing Milliner, controlling instruments, coordinating robots, scheduling tasks, managing data, and training machine learning models
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BigHat Biosciences
Agenus
HQ: United States
Website
- Description: Provider of immunotherapies and vaccines for cancer and infectious diseases, advancing antibodies that activate antitumor immunity: botensilimab (CTLA-4; Phase 2 in melanoma, MSS colorectal and pancreatic cancers), balstilimab (PD-1; backbone for combinations), zalifrelimab (CTLA-4), AGEN2373 (CD137 agonist), AGEN1571 (ILT-2 antagonist), and an anti-ILT4 antagonist developed with pembrolizumab and chemotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agenus company profile →
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Arsanis
HQ: Austria
Website
- Description: Provider of biopharmaceutical infectious disease treatments based on bacterial protein and carbohydrate antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arsanis company profile →
Dynavax
HQ: United States
Website
- Description: Provider of biopharmaceutical products to prevent infectious diseases, including HEPLISAV-B, an adult hepatitis B vaccine designed to prevent infection by all known subtypes of the virus, and CpG 1018, an adjuvant used in vaccines to enhance the immune response and contained in the HEPLISAV-B hepatitis B vaccine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dynavax company profile →
Aimmune Therapeutics
HQ: United States
Website
- Description: Provider of characterized oral desensitization immunotherapy for food allergies, including PALFORZIA to reduce the frequency and severity of reactions to accidental peanut exposure. Develops investigational therapies for food, gastrointestinal, and metabolic-related diseases, conducts human clinical trials to support marketing applications to regulatory authorities, and offers an expanded access policy compliant with FDA regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aimmune Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BigHat Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BigHat Biosciences
2.2 - Growth funds investing in similar companies to BigHat Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BigHat Biosciences
4.2 - Public trading comparable groups for BigHat Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →